Form 8-K ENZON PHARMACEUTICALS For: Dec 04
�
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
�
FORM 8-K
�
CURRENT REPORT
�
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
�
� Date of Report (Date of earliest event reported): December 4, 2014
�
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
�
Delaware (State or other jurisdiction of incorporation) |
0-12957 (Commission File Number) |
22-2372868 (IRS Employer Identification No.) |
�
20 Kingsbridge Road, Piscataway, New Jersey (Address of principal executive offices) |
08854 (Zip Code) |
�
(732) 980-4500
(Registrant’s telephone number, including area code)
�
Not Applicable
(Former name or former address, if changed since last report)
�
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
�
� | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
�
� | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
�
� | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
�
� | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
�
� |
� |
� |
�
Item 8.01 | Other Events. |
�
On December 4, 2014, the Board of Directors of Enzon Pharmaceuticals, Inc. (the “Company”) declared a special cash dividend of $0.10 per share of the Company’s common stock, payable on January 28, 2015 to stockholders of record as of January 12, 2015.
�
� |
� |
�
SIGNATURES
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
� | ENZON PHARMACEUTICALS, INC. | |
� | � | |
� | (Registrant) | |
� | � | |
Date: December 5, 2014 | By:�� | /s/ George W. Hebard III |
� | Name:�� | George W. Hebard III |
� | Title:�� | Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary |
�
� |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Investor Call Presentation available to shareholders
- FD Capital Launches Head Of Finance Recruitment Team
- BE Semiconductor Industries N.V. Announces Q1-24 Results
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!